ClinicalTrials.gg
CompletedNCT04582201Updated Dec 30, 2025

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

A Phase 1 interventional study of agenT-797 in Respiratory Distress Syndrome, Adult, sponsored by MiNK Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by MiNK Therapeutics (formerly part of Agenus Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Enrollment
173rd of 250
20 · median 52
Started
2020
with 62 others
Phase 1
23 of 324
3 open now
Registered
243rd of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 173rd largest by enrollment of the 250 interventional ones that give a count, is one of 63 that started in 2020, is one of 23 in phase 1, and was the 243rd registered.

Respiratory Distress Syndrome

1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Respiratory Distress Syndrome studies recruiting now, 117 (60%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 study of agenT-797 to treat moderate to severe acute respiratory syndrome in Coronavirus disease 2019 (COVID-19) participants.

Read the detailed description

This is a Phase 1 study to evaluate the safety and efficacy of agenT-797, an unmodified, allogeneic invariant natural killer T cells (iNKT) therapy, in participants with COVID-19, requiring mechanical ventilation, and with moderate to severe acute respiratory distress syndrome (ARDS) as determined by the Berlin definition.

The study will be conducted in 2 parts. Part 1 will employ a standard 3+3 dose escalation design of agenT-797. All participants will receive a single infusion of agenT-797. Participants will also receive other treatments and supportive care per discretion of the principal investigator. Once the maximum tolerated dose of agenT-797 has been cleared in Part 1, Part 2 of the study will be opened and enroll eligible participants in the Expansion Cohort.

A safety monitoring committee will be established to assess safety and decide on escalation to next cohort and expansion dose, as well as any protocol modification to include less severe cases.

03

Conditions studied

  • Respiratory Distress Syndrome, Adult

Keywords

  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily agree to participate and ability to provide or have duly appointed health care proxy with the authority to consent.
  • Confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by polymerase chain reaction test or equivalent approved test.
  • Inpatient hospitalization.
  • Evidence of SARS-CoV-2 infection with the diagnosis of moderate to severe ARDS per Berlin definition, no more than 2 weeks prior to study enrollment.
  • Participants, or duly appointed health care proxy with the authority to consent, must consent to placement of a central venous access line for the administration of agenT-797.

Exclusion criteria

Exclusion Criteria:

  • Currently participating and receiving study therapy of an agent that is not registered for any other indication. Note: Participants may receive the standard of care for SARS-CoV-2 infection as per institutional practices.
  • Presence of comorbidities limiting expected survival of \<1 month.
  • Any comorbidity which in the opinion of the investigator may preclude/confound study required safety and efficacy assessments.
  • cardiomyopathy.
  • Receipt of non-oncology vaccines containing live virus for prevention of infectious diseases within 4 weeks prior to first dose of study treatment.
  • Known to natural killer cells or their preservation solution.
  • Active systemic bacterial or fungal infection or viral co-infection.
  • Legally incapacitated or has limited legal capacity.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Dosage and Cohorts

    Cohort 1: 100 × 10\^6 iNKT cells; Cohort 2: 300 × 10\^6 iNKT cells; Cohort 3: 1000 × 10\^6 iNKT cells Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized participants as a single intravenous infusion.

    Drug: agenT-797

Interventions

  • agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events

    Time frame: Baseline through Month 6

  2. Number of Participants with Dose-limiting Toxicities

    Time frame: Baseline through Month 6

Secondary outcomes

  1. Time to Extubation

    Time frame: Up to Day 30

  2. Change from Baseline in C-reactive Protein (CRP)

    CRP levels will be used to assess cytokine release syndrome.

    Time frame: Baseline through Day 30 (every 12 hours, as feasible)

  3. All-cause Mortality

    Time frame: Day 30 and Month 6

  4. Decay in Quantitative Viral Burden from Upper and Lower Respiratory Tract Samples

    Time frame: Day 30

  5. Change from Baseline at Day 30 in Number of Allogeneic iNKT Cells

    Time frame: Baseline, Day 30

07

Study locations

3 sites
  • Saint John's Cancer Institute
    Santa Monica, California 90404, United States
  • Norton Cancer Institute, St. Matthews Campus
    Louisville, Kentucky 40207, United States
  • Weill Cornell Medicine New York Presbyterian
    New York, New York 10022, United States
08

References and documents

Publications

  • Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, Shaw K, van Besien K, Gomez-Arteaga A, Stevens D, Ortuzar W, Michelet X, Smith R, Moskowitz D, Masakayan R, Yigit B, Boi S, Soh KT, Chamberland J, Song X, Qin Y, Mishchenko I, Kirby M, Nasonenko V, Buffa A, Buell JS, Chand D, van Dijk M, Stebbing J, Exley MA. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nat Commun. 2024 Feb 6;15(1):974. doi: 10.1038/s41467-024-44905-z. PubMed 38321023 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Apr 2023, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 9, 2020
StartActual
Sep 21, 2020
Primary completionActual
Apr 23, 2023
CompletionActual
Apr 23, 2023
Results delay requested
Apr 5, 2024
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04582201
Lead sponsor
MiNK Therapeutics
Responsible party
Sponsor
First posted
Oct 9, 2020
Start date
Sep 21, 2020
Primary completion
Apr 23, 2023
Completion
Apr 23, 2023
Last update
Dec 30, 2025

Study contacts

Medical Director
study director · MiNK Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Invariant Natural Killer T-cells agenT-797

Start the discussion